Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multiple-Dose, Sequential Dose-Escalation Study of NBI-3001 in Patients With Recurrent or Unresponsive Solid Tumors Known to Over-Express IL-4 Receptors

NCT00039052 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT00039052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00039052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multiple-Dose, Sequential Dose-Escalation Study of NBI-3001 in Patients With Recurrent or Unresponsive Solid Tumors Known to Over-Express IL-4 Receptors
Lead sponsor
Neurocrine Biosciences
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2002
Completion date
July 31, 2008
Enrollment
Not reported
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, kidney cancer, lung cancer